| Drug Name |
Rilpivirine hydrochloride |
| Drug ID |
BADD_D01941 |
| Description |
Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients.[A31328] It is a diarylpyrimidine derivative.[A31329] The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's.[A31331] Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011.[L1030] On November 21, 2017, Rilpivirine, in combination with [dolutegravir], was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named Juluca.[L1031] Rilpivirine in combination with [cabotegravir] was granted FDA approval on 21 January 2021.[L31193] |
| Indications and Usage |
Rilpivirine, in combination with other agents, is indicated for the treatment of HIV-1 infections in antiretroviral treatment-naive patients with HIV-1 RNA ≤100,000 copies/mL and CD4+ cell count >200 cells/mm3.[L1030] The FDA combination therapy approval of rilpivirine and dolutegravir is indicated for adults with HIV-1 infections whose virus is currently suppressed (< 50 copies/ml) on a stable regimen for at least six months, without history of treatment failure and no known substitutions associated to resistance to any of the two components of the therapy.[L1031] |
| Marketing Status |
Prescription |
| ATC Code |
J05AG05 |
| DrugBank ID |
DB08864
|
| KEGG ID |
D09958
|
| MeSH ID |
D000068696
|
| PubChem ID |
11711114
|
| TTD Drug ID |
D0T6WN
|
| NDC Product Code |
12502-5500; 65977-0104; 67835-0013; 50370-0052; 53104-7734; 59676-278; 65267-501 |
| Synonyms |
Rilpivirine | Rilpivirine Hydrochloride | Hydrochloride, Rilpivirine | Rilpivirine HCl | HCl, Rilpivirine | R278474 | TMC 278 | 278, TMC | TMC278 | TMC-278 |
